BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrob Agents Chemother 2016;60:6326-32. [PMID: 27527080 DOI: 10.1128/AAC.00568-16] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL. In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother 2019;63:e02623-18. [PMID: 30642943 DOI: 10.1128/AAC.02623-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
2 Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects. Antimicrob Agents Chemother 2018;62:e02228-17. [PMID: 29437614 DOI: 10.1128/AAC.02228-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
3 Mallalieu NL, Winter E, Fettner S, Patel K, Zwanziger E, Attley G, Rodriguez I, Kano A, Salama SM, Bentley D, Geretti AM. Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers. Antimicrob Agents Chemother 2020;64:e02229-19. [PMID: 32041717 DOI: 10.1128/AAC.02229-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
4 Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother 2018;62:e01904-17. [PMID: 29084745 DOI: 10.1128/AAC.01904-17] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 10.8] [Reference Citation Analysis]
5 Remtulla R, Das SK, Levin LA. Predicting Absorption-Distribution Properties of Neuroprotective Phosphine-Borane Compounds Using In Silico Modeling and Machine Learning. Molecules 2021;26:2505. [PMID: 33923006 DOI: 10.3390/molecules26092505] [Reference Citation Analysis]
6 Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model. Antimicrob Agents Chemother 2018;62:e01969-17. [PMID: 29133570 DOI: 10.1128/AAC.01969-17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
7 Carvalhaes CG, Shortridge D, Sader HS, Castanheira M. Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. Antimicrob Agents Chemother 2020;64:e02177-19. [PMID: 31907187 DOI: 10.1128/AAC.02177-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Luci G, Mattioli F, Falcone M, Di Paolo A. Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors. Antibiotics (Basel) 2021;10:769. [PMID: 34202609 DOI: 10.3390/antibiotics10070769] [Reference Citation Analysis]
9 Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future Microbiol 2018;13:971-83. [PMID: 29692218 DOI: 10.2217/fmb-2018-0054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
10 Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs 2018;78:65-98. [PMID: 29230684 DOI: 10.1007/s40265-017-0851-9] [Cited by in Crossref: 152] [Cited by in F6Publishing: 122] [Article Influence: 50.7] [Reference Citation Analysis]
11 Tehrani KHME, Martin NI. β-lactam/β-lactamase inhibitor combinations: an update. Medchemcomm 2018;9:1439-56. [PMID: 30288219 DOI: 10.1039/c8md00342d] [Cited by in Crossref: 58] [Cited by in F6Publishing: 22] [Article Influence: 19.3] [Reference Citation Analysis]
12 Werner JP, Mitchell JM, Taracila MA, Bonomo RA, Powers RA. Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase. Protein Sci 2017;26:515-26. [PMID: 27997706 DOI: 10.1002/pro.3100] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
13 Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment. Antimicrob Agents Chemother 2018;62:e02103-17. [PMID: 29311069 DOI: 10.1128/AAC.02103-17] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
14 Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017;61:e01443-17. [PMID: 28848018 DOI: 10.1128/AAC.01443-17] [Cited by in Crossref: 149] [Cited by in F6Publishing: 81] [Article Influence: 37.3] [Reference Citation Analysis]
15 Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018;11:1461-1472. [PMID: 30254477 DOI: 10.2147/idr.s150447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 13.7] [Reference Citation Analysis]
16 Russo A. Spotlight on New Antibiotics for the Treatment of Pneumonia. Clin Med Insights Circ Respir Pulm Med 2020;14:1179548420982786. [PMID: 33424231 DOI: 10.1177/1179548420982786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis 2019;69:S565-75. [PMID: 31724043 DOI: 10.1093/cid/ciz830] [Cited by in Crossref: 100] [Cited by in F6Publishing: 71] [Article Influence: 100.0] [Reference Citation Analysis]
18 Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 2018;37:1411-9. [PMID: 29675787 DOI: 10.1007/s10096-018-3260-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
19 Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018;62:e01446-17. [PMID: 29109160 DOI: 10.1128/AAC.01446-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
20 Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front Public Health 2019;7:151. [PMID: 31245348 DOI: 10.3389/fpubh.2019.00151] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 36.5] [Reference Citation Analysis]
21 Sime FB, Pandey S, Karamujic N, Parker S, Alexander E, Loutit J, Durso S, Griffith D, Lipman J, Wallis SC, Roberts JA. Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. Antimicrob Agents Chemother 2018;62:e01306-18. [PMID: 30082292 DOI: 10.1128/AAC.01306-18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
22 Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:e01694-17. [PMID: 29038260 DOI: 10.1128/aac.01694-17] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
23 Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiol Rev 2019;43:490-516. [PMID: 31150547 DOI: 10.1093/femsre/fuz014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 36] [Article Influence: 55.0] [Reference Citation Analysis]
24 Osborn M, Stachulski N, Sun H, Blais J, Venishetty V, Raccuglia M, Kankam M, Colvin R, Segal F. A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers. Antimicrob Agents Chemother 2019;63:e02592-18. [PMID: 31061156 DOI: 10.1128/AAC.02592-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Shang Z, Chan SY, Song Q, Li P, Huang W. The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance. Research (Wash D C) 2020;2020:2016201. [PMID: 33083786 DOI: 10.34133/2020/2016201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Wong D, van Duin D. Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. Drugs 2017;77:615-28. [PMID: 28303449 DOI: 10.1007/s40265-017-0725-1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]